The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Immunocompromised Host

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Immunocompromised Host


High impact information on Immunocompromised Host


Chemical compound and disease context of Immunocompromised Host


Biological context of Immunocompromised Host


Anatomical context of Immunocompromised Host


Associations of Immunocompromised Host with chemical compounds


Gene context of Immunocompromised Host


Analytical, diagnostic and therapeutic context of Immunocompromised Host


  1. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. Erice, A., Chou, S., Biron, K.K., Stanat, S.C., Balfour, H.H., Jordan, M.C. N. Engl. J. Med. (1989) [Pubmed]
  2. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. Pahwa, S., Biron, K., Lim, W., Swenson, P., Kaplan, M.H., Sadick, N., Pahwa, R. JAMA (1988) [Pubmed]
  3. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Mitchell, C.D., Bean, B., Gentry, S.R., Groth, K.E., Boen, J.R., Balfour, H.H. Lancet (1981) [Pubmed]
  4. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lefrère, J.J., Mariotti, M., Thauvin, M. Lancet (1994) [Pubmed]
  5. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. De Clercq, E. Clin. Microbiol. Rev. (2001) [Pubmed]
  6. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. Shepp, D.H., Dandliker, P.S., Meyers, J.D. N. Engl. J. Med. (1986) [Pubmed]
  7. The dynamics of human cytomegalovirus replication in vivo. Emery, V.C., Cope, A.V., Bowen, E.F., Gor, D., Griffiths, P.D. J. Exp. Med. (1999) [Pubmed]
  8. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. Kundu, N., Beaty, T.L., Jackson, M.J., Fulton, A.M. J. Natl. Cancer Inst. (1996) [Pubmed]
  9. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Hann, I.M., Prentice, H.G., Corringham, R., Blacklock, H.A., Keaney, M., Shannon, M., Noone, P., Gascoigne, E., Fox, J., Boesen, E., Szawatkowski, M., Hoffbrand, A.V. Lancet (1982) [Pubmed]
  10. Effects of exogenous interleukin-7 on human thymus function. Okamoto, Y., Douek, D.C., McFarland, R.D., Koup, R.A. Blood (2002) [Pubmed]
  11. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. Schwartz, C., Henrickson, K.J., Roghmann, K., Powell, K. J. Clin. Oncol. (1990) [Pubmed]
  12. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Powderly, W.G., Kobayashi, G.S., Herzig, G.P., Medoff, G. Am. J. Med. (1988) [Pubmed]
  13. Current therapy of varicella zoster virus infection in immunocompromised patients. A comparison of acyclovir and vidarabine. Shepp, D.H., Dandliker, P.S., Meyers, J.D. Am. J. Med. (1988) [Pubmed]
  14. Prevention and treatment of influenza in immunocompromised patients. Hayden, F.G. Am. J. Med. (1997) [Pubmed]
  15. Glucantime-resistant visceral leishmaniasis in immunocompromised patients. Verdejo, J., Alvar, J., Polo, R.M., González-Lahoz, J.M. Am. J. Med. (1988) [Pubmed]
  16. A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype. Felsher, D.W., Denis, K.A., Weiss, D., Ando, D.T., Braun, J. Cancer Res. (1990) [Pubmed]
  17. Significance of anti-E2 in the diagnosis of HCV infection in patients on maintenance hemodialysis: anti-E2 is frequently detected among anti-HCV antibody-negative patients. Lee, D.S., Lesniewski, R.R., Sung, Y.C., Min, W.K., Park, S.G., Lee, K.H., Kim, H.S. J. Am. Soc. Nephrol. (1996) [Pubmed]
  18. Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora. Andremont, A., Raibaud, P., Tancrède, C. J. Infect. Dis. (1983) [Pubmed]
  19. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Soderberg, C., Sumitran-Karuppan, S., Ljungman, P., Moller, E. Transplantation (1996) [Pubmed]
  20. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. Forthal, D.N., Landucci, G., Haubrich, R., Keenan, B., Kuppermann, B.D., Tilles, J.G., Kaplan, J. J. Infect. Dis. (1999) [Pubmed]
  21. Enhancement of intracellular replication of Toxoplasma gondii by IL-6. Interactions with IFN-gamma and TNF-alpha. Beaman, M.H., Hunter, C.A., Remington, J.S. J. Immunol. (1994) [Pubmed]
  22. Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients. Boivin, G., Quirk, M.R., Kringstad, B.A., Germain, M., Jordan, M.C. Antimicrob. Agents Chemother. (1997) [Pubmed]
  23. Fms-like tyrosine kinase 3-based immunoprophylaxis against infection is improved by adjuvant treatment with anti-interleukin-10 antibody. Das, L., DeVecchio, J., Heinzel, F.P. J. Infect. Dis. (2005) [Pubmed]
  24. Cefodizime as a biological response modifier: a review of its in-vivo, ex-vivo and in-vitro immunomodulatory properties. Labro, M.T. J. Antimicrob. Chemother. (1990) [Pubmed]
  25. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. Burg, J.L., Grover, C.M., Pouletty, P., Boothroyd, J.C. J. Clin. Microbiol. (1989) [Pubmed]
  26. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. Komschlies, K.L., Gregorio, T.A., Gruys, M.E., Back, T.C., Faltynek, C.R., Wiltrout, R.H. J. Immunol. (1994) [Pubmed]
  27. Enhanced dendritic cell-driven proliferation and anti-HIV activity of CD8(+) T cells by a new phenothiazine derivative, aminoperazine. Lu, W., Achour, A., Arlie, M., Cao, L., Andrieu, J.M. J. Immunol. (2001) [Pubmed]
  28. A controlled study of ticarcillin plus clavulanic acid versus piperacillin as empiric therapy for fever in the immunocompromised host. Williams, M.E., Harman, C., Scheld, M., Hess, C.E., Donowitz, G.R. Am. J. Med. (1985) [Pubmed]
  29. Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients. Bernstein, J.M., Gorse, G.J., Linzmayer, M.I., Pegram, P.S., Levin, R.D., Brummett, R.E., Markowitz, N., Saravolatz, L.D., Lorber, R.R. Arch. Intern. Med. (1986) [Pubmed]
  30. Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Michailowsky, V., Silva, N.M., Rocha, C.D., Vieira, L.Q., Lannes-Vieira, J., Gazzinelli, R.T. Am. J. Pathol. (2001) [Pubmed]
  31. Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients. Agustí, C., Rañó, A., Rovira, M., Filella, X., Benito, N., Moreno, A., Torres, A. Thorax (2004) [Pubmed]
  32. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Tangye, S.G., van de Weerdt, B.C., Avery, D.T., Hodgkin, P.D. Eur. J. Immunol. (2002) [Pubmed]
  33. Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection. Schirren, C.A., Jung, M., Worzfeld, T., Mamin, M., Baretton, G.B., Gruener, N.H., Gerlach, J.T., Diepolder, H.M., Zachoval, R., Pape, G.R. Liver Transpl. (2000) [Pubmed]
  34. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. Huang, W., Na, L., Fidel, P.L., Schwarzenberger, P. J. Infect. Dis. (2004) [Pubmed]
  35. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. Erice, A., Jordan, M.C., Chace, B.A., Fletcher, C., Chinnock, B.J., Balfour, H.H. JAMA (1987) [Pubmed]
  36. Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion. Spector, S.A., Hintz, M., Wyborny, C., Connor, J.D., Keeney, R.E., Liao, S. Am. J. Med. (1982) [Pubmed]
  37. Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. Kern, E.R., Hartline, C.B., Rybak, R.J., Drach, J.C., Townsend, L.B., Biron, K.K., Bidanset, D.J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  38. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Snoeck, R., Holý, A., Dewolf-Peeters, C., Van Den Oord, J., De Clercq, E., Andrei, G. Antimicrob. Agents Chemother. (2002) [Pubmed]
  39. Chiral chemical synthesis of DNA containing (S)-9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) and effects on thermal stability, duplex structure, and thermodynamics of duplex formation. Marshalko, S.J., Schweitzer, B.I., Beardsley, G.P. Biochemistry (1995) [Pubmed]
WikiGenes - Universities